The role of the stomach in the control of appetite and the secretion of satiation peptides

Am J Physiol Endocrinol Metab. 2012 Mar 15;302(6):E666-73. doi: 10.1152/ajpendo.00457.2011. Epub 2012 Jan 3.

Abstract

It is widely accepted that gastric parameters such as gastric distention provide a direct negative feedback signal to inhibit eating; moreover, gastric and intestinal signals have been reported to synergize to promote satiation. However, there are few human data exploring the potential interaction effects of gastric and intestinal signals in the short-term control of appetite and the secretion of satiation peptides. We performed experiments in healthy subjects receiving either a rapid intragastric load or a continuous intraduodenal infusion of glucose or a mixed liquid meal. Intraduodenal infusions (3 kcal/min) were at rates comparable with the duodenal delivery of these nutrients under physiological conditions. Intraduodenal infusions of glucose elicited only weak effects on appetite and the secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). In contrast, identical amounts of glucose delivered intragastrically markedly suppressed appetite (P < 0.05) paralleled by greatly increased plasma levels of GLP-1 and PYY (≤3-fold, P < 0.05). Administration of the mixed liquid meal showed a comparable phenomenon. In contrast to GLP-1 and PYY, plasma ghrelin was suppressed to a similar degree with both intragastric and intraduodenal nutrients. Our data confirm that the stomach is an important element in the short-term control of appetite and suggest that gastric and intestinal signals interact to mediate early fullness and satiation potentially by increased GLP-1 and PYY secretions.

Trial registration: ClinicalTrials.gov NCT01304823.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Appetite / physiology*
  • Blood Glucose / metabolism
  • Double-Blind Method
  • Duodenum / physiology
  • Female
  • Gastric Emptying / physiology
  • Ghrelin / blood
  • Glucagon / blood
  • Glucagon-Like Peptide 1 / blood
  • Glucose / administration & dosage
  • Glucose / pharmacology
  • Humans
  • Insulin / blood
  • Intubation, Gastrointestinal
  • Male
  • Neuropeptides / metabolism*
  • Peptide YY / blood
  • Satiation / physiology*
  • Stomach / physiology*
  • Young Adult

Substances

  • Blood Glucose
  • Ghrelin
  • Insulin
  • Neuropeptides
  • Peptide YY
  • Glucagon-Like Peptide 1
  • Glucagon
  • Glucose

Associated data

  • ClinicalTrials.gov/NCT01304823